Full-Time

Territory Leader

San Antonio

Posted on 9/26/2025

Tarsus Pharamceuticals

Tarsus Pharamceuticals

201-500 employees

Biopharma developing eye-care therapies

Compensation Overview

$120k - $152k/yr

+ Bonus + Stock Equity

San Antonio, TX, USA

In Person

Field-based role; requires 40-50% travel, including occasional travel to Irvine, CA.

Category
Sales & Account Management (3)
, ,
Required Skills
Management
Data Analysis
Requirements
  • Bachelor’s degree in business, science, or related field or commensurate experience
  • 2+ years pharmaceutical sales / relevant healthcare sales experience or a proven track record of business to business sales - required
Responsibilities
  • Experts in eye care clinical information: anatomy, disease state, products, XDEMVY and office treatment patterns
  • Experts in selling skills and account development including building relationships with all key stakeholders
  • Experts in pull through tactics with a full understanding of managed care hurdles
  • Understand all functions within an ophthalmology/optometry practice and how their roles impact product prescribing and pull through
  • Maximize managed care opportunities within the territory and have an understanding of how it impacts the District, Region and Nation and share important feedback
  • Understand key opinion leaders within respective geographies and foster engagement with Tarsus leadership
  • As eye care experts, champion compliant promotion in alignment with our corporate values
  • Drive top tier execution by exceeding sales performance goals and key productivity metrics across the territory
  • Use expert analytical skills to guide highly productive activity – prioritize key customer engagements, drive reach and frequency to extend depth and breadth of product trial and utilization
  • Drive a successful launch and ongoing performance by monitoring all key performance metrics weekly, monthly, quarterly, and annually – ability to adjust approach as needed based on data
  • Ensure actionable business plans are set - align all selling activities to drive impact
  • Share ongoing insights with leadership and internal stakeholders to ensure feedback is captured
  • Personal accountability for driving the highest standards of ethics and compliance
  • Drive our culture of commitment, empowerment and teamwork which includes extreme ownership, high accountability, continuous improvement and relentless pursuit of excellence
  • Achieve success and be prepared to adapt in a complex selling environment partnering with many stakeholders: district leaders, marketing, market access, medical affairs, sales ops, inside sales, training, and other important stakeholders
  • Provide frontline feedback and intel to sales leadership and the broader organization
  • Ensure PDMA compliance and adhere to all company & industry compliance guidelines
  • Share ongoing best practices among peers and leadership to elevate national performance
  • Maximize all key resources that lead to territory success
Desired Qualifications
  • Strong preference for proven pharmaceutical launch experience
  • Eye Care experience- preferred
  • Geography - San Antonio resident preferred
Tarsus Pharamceuticals

Tarsus Pharamceuticals

View

Tarsus Pharmaceuticals develops treatments for eye care and infectious diseases. Its FDA-approved product, XDEMVY (lotilaner ophthalmic solution 0.25%), treats Demodex Blepharitis by killing Demodex mites on the eyelids. The company also has a pipeline targeting conditions like Lyme Disease Prevention, Meibomian Gland Disease, and Rosacea, and it earns revenue from selling approved products and collaborating with partners. Its goal is to address unmet medical needs by developing, commercializing, and expanding collaborations to reach more patients.

Company Size

201-500

Company Stage

IPO

Headquarters

Irvine, California

Founded

2017

Simplify Jobs

Simplify's Take

What believers are saying

  • XDEMVY nets $145 million Q1 2026 sales, up 85% year-over-year.
  • 2026 guidance projects $670-$700 million XDEMVY sales, 50% growth.
  • $200 million Pharmakon financing supports sales force expansion without dilution.

What critics are saying

  • ICRx Cliradex wipes erode XDEMVY sales by 15-20% within 6-12 months.
  • TP-05 CALLIOPE trial fails efficacy, halts Phase 3 in 12-18 months.
  • Aldeyra reproxalap captures 25% Demodex market share post-2027 approval.

What makes Tarsus Pharamceuticals unique

  • XDEMVY is the only FDA-approved treatment for Demodex blepharitis.
  • TP-05 advances as first-in-class oral Lyme disease preventive in Phase 2 CALLIOPE trial.
  • TP-04 targets untreated ocular rosacea market in Phase 2 with H1 2027 data.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Paid Vacation

Hybrid Work Options

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

0%

2 year growth

2%
Yahoo Finance
Apr 3rd, 2026
Tarsus Pharmaceuticals doses first patient in Phase 2 Lyme disease prevention trial with TP-05

Tarsus Pharmaceuticals has dosed the first participant in its Phase 2 Calliope trial of TP-05, an investigational oral therapy aimed at preventing Lyme disease in approximately 700 at-risk adults across endemic US regions. The programme targets a significant unmet need as a potential first-in-class, non-vaccine prophylactic for Lyme disease, where no FDA-approved preventive drugs currently exist. Whilst the trial marks progress, near-term investment focus remains on XDEMVY adoption and margins. The company recently received a $15 million milestone payment tied to TP-03 approval in China, highlighting monetisation of its lotilaner platform beyond the US. Analyst projections for Tarsus vary widely, with some forecasting $847 million revenue and $237 million earnings by 2028, whilst more cautious estimates suggest $988 million revenue and $188 million earnings by 2029.

Yahoo Finance
Mar 24th, 2026
Tarsus Pharma CHRO sells $839K in shares via mandatory RSU vesting amid 20% stock surge

Dianne Whitfield, Chief Human Resources Officer at Tarsus Pharmaceuticals, sold 12,274 shares of common stock worth approximately $839,000 between 17 and 19 March 2026. The sale represented 25.95% of her direct holdings, reducing her position from 47,302 to 35,028 shares. The transaction was a mandatory "sell to cover" arrangement tied to RSU vesting for tax withholding purposes, rather than a discretionary sale. Shares sold at a weighted average price of $68.36. Tarsus Pharmaceuticals generated $451.4 million in net product sales in 2025, more than doubling from the prior year, driven by adoption of its lead product XDEMVY. The company narrowed its net loss to $66.4 million and ended 2025 with over $417 million in cash and marketable securities.

Yahoo Finance
Feb 24th, 2026
Tarsus Pharmaceuticals projects $670M–$700M 2026 sales as XDEMVY hits profitability

Tarsus Pharmaceuticals reported $450 million in full-year net sales for 2025, with its XDEMVY treatment achieving product-line profitability. The company has expanded its addressable market from nine million to 25 million Americans with Demodex blepharitis as screening becomes routine amongst eye care professionals. The firm projected 2026 net product sales between $670 million and $700 million, representing approximately 50% annual growth at the midpoint. Direct-to-consumer awareness reached 25% amongst surveyed patients, significantly increasing treatment requests. Tarsus plans to expand its sales force by 15 to 20 key account leaders and will initiate a Phase II trial for TP-05 in Lyme disease prevention in Q2 2026. The company has also launched the first Phase II trial for TP-04 in Ocular Rosacea, a category with no currently approved FDA treatments.

GlobeNewswire
Mar 13th, 2025
Tarsus Announces Pricing of Upsized $125.0 Million Public Offering

IRVINE, Calif., March 12, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) (the “Company” or “Tarsus”) today announced the pricing of...

MarketBeat
Nov 22nd, 2024
Mutual of America Capital Management LLC Invests $4.29 Million in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

Mutual of America Capital Management LLC invests $4.29 million in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS).

INACTIVE